
Lin (Counts)
17000
16000
15000
14000
13000
12000
11000
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
2
10
20
30
2-Thela - Scale

Fig. 1-A



Fig. 1-B


Lin (Counts)
17000
16000
15000
14000
13000
12000
11000
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
2
10
20
30
2-Theta - Scale

Fig. 1-C



Fig. 2-A



Fig. 2-B



Fig. 2-C


Size: 1.0400 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN
247.96°C
77.37 J/g
250.67°C
Heat Flow (W/g)
Exo Up
Temperature (°C)
Universal V2 5I
1
0
-1
-2
-3
-4
0
50
100
150
200
250
300

Fig. 2-D



Fig. 2-E



Fig. 3-A


Transmittance
96
94
92
90
88
3500
2500
1800
1400
1000
600
Wavenumber (cm-1)

Fig. 3-B



Fig. 3-C


110
90
70
50
Transmittance
3500
2500
1800
1400
1000
Wavenumber (cm-1)

Fig. 3-D



Fig. 4



Fig. 5



Fig. 6-A



Fig. 7



Fig. 8



Fig. 9



Fig. 10



Fig. 11


Normalized Intensity
Form I Peak
(b)
(a)
5
10
15
20
25
30
Degrees Two Theta

Fig. 12



Fig. 13



Fig. 14


C+
End Point
C-
100.3
98.3
100.3
98.1 A+
100.3
99.2
100.5
99.5
A-
B-
B-
Actual Purity
Purity
Cooling Rate

Fig. 15


Half Normal Plot
B
A
AB
0.00
0.38
0.76
1.14
1.53
Effect
99
97
95
90
85
80
70
60
40
20
0
Half Normal % Probability
Purity
A: Cooling Rate
B: Purity
C: End Point

Fig. 16


Interaction Graph
Actual Purity
100.50
100.10
99.70
99.30
98.90
98.50
98.10
B+
B-
A-
A+
Interaction of A: Cooling Rate and B: Purity

Fig. 17


C+
End Point
C-
A+
A-
B-
B-
Purity
Actual Form
Cooling Rate
0
0
0
0
29
9
31
0

Fig. 18



Fig. 19



Interaction of B: Purity and C: End Point

Fig. 20



Fig. 21


Peak = 241.462 °C
Onset = 230.599 °C
Area = 84.525 mJ
X1 = 232.698 °C
Y1 = 7.1811 mW
X2 = 243.648 °C
Y2 = 7.7216 mW
Onset = 245.008 °C
Area = 77.939 mJ
Delta H = 40.215 J/g
X1 = 243.648 °C
Y1 = 7.7216 mW
X2 = 251.200 °C
Y2 = 8.1761 mW
Y1 = 6.3921 mW
X1 = 88.830 °C
Y2 = 4.8904 mW
X2 = 100.008 °C
Onset = 103.241 °C
Peak = 108.168 °C
Heat Flow Endo Up (mW)
Temperature (°C)

Fig. 22

Systolic Blood Pressure in Angiotensin II- or Vehicle-Infused Rats



Fig. 23

Eplerenone Prevents the Vascular Inflammatory Lesions in Angiotensin II/Salt Hypertensive Rats



Vehicle

Eplerenone

Fig. 24

COX-2 is Not Expressed in the Heart of 1% NaCl-Drinking Rats



1% NaCl

FIGURE 25

Angiotensin II/NaCl Treatment Induces COX-2 Expression in the Media of Coronary Arteries in Rats



Angiotensin II + NaCl

FIGURE 26

Eplerenone Prevents COX-2 Expression in Coronary Arteries in Angiotensin II/Salt Hypertensive Rats

Angiotensin II + NaCl + Eplerenone

FIGURE 27

Osteopontin is Not Expressed in the Normal Heart



Saline-Drinking Control

FIGURE 28

Eplerenone Prevents Osteopontin Expression in Coronary Arteries of Aldosterone/Salt/Uninephrectomized Rats



Aldosterone/Salt



Aldosterone/Salt with Eplerenone

FIGURE 29



FIGURE 30

Eplerenone Prevents Myocardial COX-2 Upregulation in Aldosterone/Salt Hypertensive Rats



••• P<.001 vs NaCl
†† P<.01 vs Aldo/NaCl

FIGURE 31

Eplerenone Prevents Myocardial Injury in Aldosterone/Salt/Uninephrectomized Rats



FIGURE 32

COX-2 and Osteopontin are Co-Expressed in Similar Regions in the Coronary Arterial Wall



COX-2 Osteopontin

FIGURE 33

Potential Mechanisms of Aldosterone-Induced Vascular Inflammation and Injury



FIGURE 34

Urinary Protein Excretion in Saline-Drinking Stroke-Prone SHR



*** P<.001vs Captopril
P<.001 vs Captopril+Ang II+Epl

FIGURE 35

Histopathologic Scores for Renal Injury in Saline-Drinking Stroke-Prone SHR

	Vehicle (n=8)	Capt (n=10)	Capt ALDO (n=7)	Capt Ang II (n=7)	Capt+Ang II+ Eplerenone (n=7)
Renal arteriopathy (lesions/100 glom.)	18±3**	0±0	15±1**	16±2**	3.6±1**, ##
Glomerular damage (lesions/100 glom.)	24±3**	0±0	26±1**	15±3**	3.2±1**, ##

** P<.001 vs Captopril
P<.001 vs Captopril & Ang II

FIGURE 36

Eplerenone Prolongs Survival and Protects Against Stroke in Saline-Drinking Stroke-Prone SHR



FIGURE 37

Eplerenone Protects Against Cerebral Injury in Saline-Drinking Stroke-Prone SHR



Vehicle-Treated SHRSP

Eplerenone-Treated SHRSP

FIGURE 38


Time-Course Expression of Myocardial COX-2 in Aldosterone-Salt Hypertensive Rats
NaCl
Aldosterone + NaCl
Aldosterone + NaCl+ Eplerenone
Relative mRNA Expression
0
1
2
3
4
5
Day 7
Day 14
Day 30

FIGURE 39

Time-Course Expression of Myocardial Osteopontin in Aldosterone-Salt Hypertensive Rats



FIGURE 40

Time-Course Expression of Myocardial MCP-1 in Aldosterone-Salt Hypertensive Rats



FIGURE 41

Time-Course Expression of Myocardial ICAM-1 and VCAM-1 in Aldosterone-Salt Hypertensive Rats



FIGURE 42


Eplerenone Reduces Systolic Blood Pressure
Blood Pressure (mmHg)
Vehicle/1%NaCl
Aldosterone/1%NaCl
Aldosterone/1% NaCl eplerenone
220
200
180
160
140
120
100
1
5
9
1
17
21
25
29
Days of Infusion
* p<0.05 vs. Veh + p<0.05 vs. Aldo

FIG. 43



+ p<0.05 vs. Aldo

* p<0.05 vs. Veh

FIG 44


28 Day Circulating Osteopontin Levels
osteopontin (ng/ml)
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
*
+
VEH/1%NaCl
ALDO/1%NaCl
ALDO/1%NaCl+epl
* p<0.05 vs VEH; + p<0.05 vs ALDO/1%NaCl

FIG. 45



* p<0.05 vs. Veh + p<0.05 vs. Aldo

FIG. 46